8-K: SELLAS Reports Q3 2025 Results, Advances AML Pipeline

SELLAS Life Sciences Group reported third quarter 2025 financial results, highlighted progress in its AML-focused pipeline, and announced a strengthened cash position.

Summary

• Net loss for the third quarter of 2025 was $6.8 million, an improvement from $7.1 million for the same period in 2024.
• Basic and diluted net loss per common share for Q3 2025 was $0.06, compared to $0.10 in Q3 2024.
• Research and development expenses decreased to $4.2 million in Q3 2025 from $4.4 million in Q3 2024.
• General and administrative expenses decreased to $2.9 million in Q3 2025 from $3.0 million in Q3 2024.
• Cash and cash equivalents totaled $44.3 million as of September 30, 2025.
• An additional $29.1 million in net proceeds from warrant exercises was received in October 2025.
• The Phase 3 REGAL trial for GPS in AML is advancing as planned, with final analysis anticipated by year-end 2025.
• Positive Phase 2 data for SLS009 in relapsed or refractory AML were accepted for presentation at the 67th ASH Annual Meeting in December 2025.
• Enrollment for an 80-patient trial of SLS009 in newly diagnosed AML patients is expected to begin in the first quarter of 2026.
• Preclinical data for SLS009 in T-cell prolymphocytic leukemia (T-PLL) demonstrated statistically significant survival benefits and were presented at ESMO 2025.

Sentiment

Score: 8

Explanation: The company reported improved financial metrics with reduced losses and a significantly strengthened cash position due to warrant exercises. Clinical programs, GPS and SLS009, are advancing positively with key data presentations and trial initiations planned, indicating strong operational execution and potential future catalysts. The only notable negative is the inherent uncertainty in the exact timing of the event-driven Phase 3 trial analysis.

Positives

• Reduced net loss for Q3 2025 ($6.8 million) compared to Q3 2024 ($7.1 million), indicating improved financial performance.
• Reduced net loss per share for Q3 2025 ($0.06) compared to Q3 2024 ($0.10).
• Decreased research and development expenses in Q3 2025 ($4.2 million) and for the nine months ended September 30, 2025 ($11.3 million).
• Decreased general and administrative expenses in Q3 2025 ($2.9 million) and for the nine months ended September 30, 2025 ($8.7 million).
• Strong cash position with $44.3 million as of September 30, 2025, significantly bolstered by an additional $29.1 million in net proceeds from warrant exercises in October 2025.
• The Phase 3 REGAL trial for GPS in AML is on track and received a positive Independent Data Monitoring Committee (IDMC) recommendation in August to continue without modification.
• Positive Phase 2 data for SLS009 in relapsed or refractory AML were accepted for presentation at the prestigious 67th ASH Annual Meeting.
• Preclinical data for SLS009 demonstrated statistically significant survival benefits in T-PLL, supporting its therapeutic potential across multiple hematologic malignancies.
• Management believes the company is entering a transformative period of growth and value creation with multiple catalysts ahead.

Negatives

• The company continues to report a net loss, totaling $6.8 million for Q3 2025 and $19.2 million for the nine months ended September 30, 2025.
• The final analysis for the Phase 3 REGAL trial is event-driven, making its exact timing uncertain and potentially different from current expectations.

Risks

• The final analysis for the Phase 3 REGAL trial is event-driven, making it difficult to predict with certainty, and it may occur at a different time than currently expected.
• Risks and uncertainties are inherent in oncology product development and achieving clinical success.
• There is uncertainty regarding regulatory approval for product candidates.
• Other risks and uncertainties affecting SELLAS and its development programs are detailed in its Annual Report on Form 10-K filed on March 20, 2025, and in its other SEC filings.

Future Outlook

SELLAS anticipates the final analysis of the Phase 3 REGAL trial for GPS by year-end 2025, though the event-driven nature makes the exact timing uncertain. Enrollment for an 80-patient trial of SLS009 in newly diagnosed AML patients is expected to commence in the first quarter of 2026. The company believes it is entering a transformative period of growth and value creation with multiple catalysts ahead.

Management Comments

• "We remain highly encouraged by the continued, strong execution across our programs and the expanding body of clinical and preclinical data reinforcing the strength of our AML-focused pipeline."
• "The Phase 3 REGAL trial of GPS is advancing as planned as highlighted by the key opinion leaders at our recent R&D event."
• "Momentum around SLS009 also continues to build—our positive Phase 2 data were accepted for presentation at the upcoming ASH Annual Meeting, and we recently presented preclinical results at ESMO demonstrating clear survival benefits in T-PLL."
• "Our recent R&D Day was a resounding success and provided an excellent opportunity to share program updates and hear directly from leading experts who expressed genuine enthusiasm for both GPS and SLS009."
• "These achievements highlight the breadth and promise of our pipeline and underscore the complementary potential of our two programs to meaningfully improve outcomes for patients with AML and other hematologic cancers."
• "With a strong financial foundation following the recent warrant exercises and multiple catalysts ahead, we believe SELLAS is entering a transformative period of growth and value creation."

Industry Context

SELLAS operates in the highly competitive and innovative biopharmaceutical sector, specifically targeting hematologic malignancies like Acute Myeloid Leukemia (AML) and T-cell prolymphocytic leukemia (T-PLL). The acceptance of SLS009 data for presentation at the ASH Annual Meeting and preclinical data at ESMO indicates engagement with leading scientific forums, crucial for validating novel therapies in oncology. The focus on CDK9 inhibition and WT1 protein targeting represents distinct approaches within cancer therapy, aiming to address unmet needs in patient populations with poor prognoses, such as those with ASXL1 mutations in AML.

Comparison to Industry Standards

• The positive Phase 2 data for SLS009 in relapsed/refractory AML, particularly in combination with azacitidine and venetoclax, is significant given the challenging nature of this patient population. Venetoclax-based regimens are a standard of care, and demonstrating improved outcomes or efficacy in refractory settings could position SLS009 favorably against existing therapies or other investigational CDK9 inhibitors like those from Takeda (pevonedistat) or Cyclacel (fadraciclib) by offering a differentiated toxicity profile or enhanced potency.
• The statistically significant survival benefit of SLS009 in T-PLL preclinical models, both as monotherapy and in combination with venetoclax, suggests potential differentiation in a rare and aggressive hematologic malignancy where treatment options are limited. This could compare favorably to current T-PLL treatments which often have limited durability, such as alemtuzumab or pentostatin, by offering a novel mechanism of action.
• The advancement of the Phase 3 REGAL trial for GPS in AML (CR2) following a positive IDMC recommendation indicates the program is progressing through a critical late-stage clinical hurdle, aligning with industry best practices for drug development in oncology. This positions GPS against other investigational or approved maintenance therapies in AML, such as gilteritinib for FLT3-mutated AML, by targeting the WT1 protein, which is broadly expressed across AML.

Stakeholder Impact

• Shareholders: Potentially positive due to a significantly strengthened cash position, reduced net loss, and advancing clinical pipeline with multiple catalysts, which could lead to future value creation. However, the uncertainty of the REGAL trial's final analysis timing introduces some risk.
• Patients (AML, T-PLL): Positive impact from the continued development of GPS and SLS009, offering potential new therapeutic options for challenging cancer indications.
• Employees: Continued progress in clinical programs and a stronger financial foundation could provide stability and opportunities within the company.

Next Steps

• Conduct the final analysis of the Phase 3 REGAL trial for GPS, anticipated by year-end 2025.
• Present positive Phase 2 data for SLS009 in R/R AML at the 67th ASH Annual Meeting and Exposition (December 6-9, 2025).
• Initiate an 80-patient trial for SLS009 in newly diagnosed AML patients and those refractory to AZA/VEN treatment, expected in Q1 2026.

Key Dates

Recommendation

While SELLAS has demonstrated improved financial performance with reduced losses and a significantly bolstered cash position from warrant exercises, the company remains in a clinical development stage with no revenue from product sales. The advancement of the Phase 3 REGAL trial and positive Phase 2 data for SLS009 are encouraging, but the final analysis of REGAL is event-driven and its exact timing is uncertain. The stock carries inherent risks associated with oncology drug development, including regulatory approval uncertainty. The current news suggests positive operational momentum and financial stability for ongoing trials, but a 'hold' recommendation is prudent until more definitive clinical outcomes, particularly from the REGAL trial's final analysis, are available to fully assess long-term value creation.

Keywords

SELLAS Life Sciences, SLS, AML, Acute Myeloid Leukemia, GPS, SLS009, CDK9 Inhibitor, REGAL trial, ASH 2025, ESMO 2025, Biopharmaceutical, Oncology, Clinical Trials, Financial Results, Warrant Exercises, Cash Position